TY - JOUR
T1 - Cost-effectiveness analysis of the diarrhea alleviation through zinc and oral rehydration therapy (DAZT) program in rural Gujarat India
T2 - An application of the net-benefit regression framework
AU - Shillcutt, Samuel D.
AU - LeFevre, Amnesty E.
AU - Fischer-Walker, Christa L.
AU - Taneja, Sunita
AU - Black, Robert E.
AU - Mazumder, Sarmila
N1 - Funding Information:
This work was supported by the Bill and Melinda Gates Foundation. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data in the study and had final responsibility for the deci‑ sion to submit for publication.
Funding Information:
The DAZT Program was a partnership between the Micronutrients Initiative, Family Health International‑360, UNICEF, the US Fund for UNICEF, and Johns Hopkins Bloomberg School of Public Health that was made possible only through the generous support of the Bill and Melinda Gates Foundation (BMGF). The BMGF had no role in the data collection or analysis of this study. Alan Sorkin provided stewardship from the conception of the idea through the analysis, and the Johns Hopkins Biostatistics Center provided technical support.
Publisher Copyright:
© 2017 The Author(s).
PY - 2017/6/8
Y1 - 2017/6/8
N2 - Background: This study evaluates the cost-effectiveness of the DAZT program for scaling up treatment of acute child diarrhea in Gujarat India using a net-benefit regression framework. Methods: Costs were calculated from societal and caregivers' perspectives and effectiveness was assessed in terms of coverage of zinc and both zinc and Oral Rehydration Salt. Regression models were tested in simple linear regression, with a specified set of covariates, and with a specified set of covariates and interaction terms using linear regression with endogenous treatment effects was used as the reference case. Results: The DAZT program was cost-effective with over 95% certainty above $5.50 and $7.50 per appropriately treated child in the unadjusted and adjusted models respectively, with specifications including interaction terms being cost-effective with 85-97% certainty. Discussion: Findings from this study should be combined with other evidence when considering decisions to scale up programs such as the DAZT program to promote the use of ORS and zinc to treat child diarrhea.
AB - Background: This study evaluates the cost-effectiveness of the DAZT program for scaling up treatment of acute child diarrhea in Gujarat India using a net-benefit regression framework. Methods: Costs were calculated from societal and caregivers' perspectives and effectiveness was assessed in terms of coverage of zinc and both zinc and Oral Rehydration Salt. Regression models were tested in simple linear regression, with a specified set of covariates, and with a specified set of covariates and interaction terms using linear regression with endogenous treatment effects was used as the reference case. Results: The DAZT program was cost-effective with over 95% certainty above $5.50 and $7.50 per appropriately treated child in the unadjusted and adjusted models respectively, with specifications including interaction terms being cost-effective with 85-97% certainty. Discussion: Findings from this study should be combined with other evidence when considering decisions to scale up programs such as the DAZT program to promote the use of ORS and zinc to treat child diarrhea.
KW - Cost-effectiveness
KW - Developing countries
KW - Diarrhea
KW - Implementation science
KW - India
KW - Net-benefit regression
KW - Oral rehydration salts
KW - Zinc
UR - http://www.scopus.com/inward/record.url?scp=85020392252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020392252&partnerID=8YFLogxK
U2 - 10.1186/s12962-017-0070-y
DO - 10.1186/s12962-017-0070-y
M3 - Article
C2 - 28603456
AN - SCOPUS:85020392252
VL - 15
JO - Cost Effectiveness and Resource Allocation
JF - Cost Effectiveness and Resource Allocation
SN - 1478-7547
IS - 1
M1 - 9
ER -